GeoVax Labs (GOVX) Q4 2024 earnings summary

Executive summary

• Secured a nearly $400 million BARDA Project NextGen Award to advance the next-generation COVID-19 vaccine, GEO-CM04S1, with manufacturing and clinical trial preparations underway and a Phase 2b trial planned.

• Advanced multiple clinical programs, including COVID-19, Mpox/Smallpox vaccines, and Gedeptin for head and neck cancer, with clinical evaluation for GEO-MVA expected in H2 2025 and Gedeptin Phase 2 trial initiation in mid-to-late 2025.

• Strengthened manufacturing capabilities and expanded intellectual property portfolio to over 130 patents across 23 families.

• Strategic focus remains on developing innovative cancer therapies and infectious disease vaccines, emphasizing expedited registration pathways and global partnerships.

Financial highlights

• 2024 revenues were $4 million, driven by the BARDA contract, compared to zero in 2023.

• Research and development expenses rose 14% year-over-year to $23.7 million, mainly due to manufacturing and BARDA-related costs.

• General and administrative expenses decreased 11% to $5.4 million, reflecting lower stock-based compensation and consulting costs.

• Net loss for 2024 was $25 million ($4.82 per share), slightly improved from $26 million ($14.29 per share) in 2023.

• Cash balance at year-end was $5.5 million, with $24.7 million used in operations and $23.8 million raised through financing.

Outlook and guidance

• Priorities for 2025 include advancing GEO-CM04S1, especially under Project NextGen, and establishing global partnerships.

• Data from GEO-CM04S1 booster study in healthy adults expected in H1 2025, with multiple clinical data presentations planned at major conferences.

• Clinical evaluation of GEO-MVA for Mpox/Smallpox set to begin in H2 2025.

• Anticipates continued updates on advanced MVA manufacturing and expects Gedeptin Phase 2 trial to start in mid-to-late 2025.

• Funding needs will focus on clinical programs for CM04S1, Gedeptin, and GEO-MVA, with strategies including partnerships and additional financing.